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A retrospective study on Equine Herpes Virus type-1 associated 
myeloencephalopathy in France (2008-2011) 
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 MATERIALS ET METHODS 
Recognition of equine herpesvirus-1 associated 
myeloencephalopathy (EHM) can be troublesome (see Photos), 
but early recognition and knowledge on risk factors are 
considered primordial for outbreaks prevention and control.   
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Most showed ataxia, paresis and a cauda equina syndrome, yet presence of other neurological signs was variable. Statistical analysis 
identified the following variables to be significantly associated to EHM compared to controls: introduction of a new horse to the herd, 
cauda equina syndrome, larger herd size, saddle horses and month of occurrence. Risk factors were found to be similar to previous 
studies, therefore strengthening their significance to the spread of EHM. 
 
Therefore this study describes 26 EHM cases reported through a passive epidemiosurveillance program in France from 2008-2011 and 
compares them to control cases (31 horses potentially suffering an infectious neurological disease, but negative for EHM) to identify 
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Table 3. Clinical variables of horses with equine 
herpesvirus-1 associated myeloencephalopathy and 
control horsesC 
The fatality rate of EHM cases was 46% and the majority consisted of isolated cases. Most showed ataxia or paresis and a cauda 
equina syndrome, but the clinical picture was variable.  





   P value (two-sample wilcoxon rank-
sum test) 
Rectal temperature  
(°C;  
mean  SD, range, n) 
38.1  1.6 
range 35.0-40.8 
n = 17 
38.3  1.0 
range 37.0-40.5 
n = 22 
0.72 
 N n % N n % P value OR CI 95% 
Fever 11 21 52% 7 23 30% 0.14 1.46 0.73-8.63 
Respiratory signs 8 18 44% 10 25 40% 0.74 1.23 0.37-4.03 
Abnormal posture 5 21 24% 5 24 21% 0.81 1.19 0.29-4.85 





7 16 44% 15 27 56% 0.38 0.60 0.19-1.90 
Abnormal behaviour
$
 12 22 55% 17 27 63% 0.55 0.71 0.22-2.22 
Abnormal head 
position 





8 21 38% 17 27 63% 0.09* 0.36 0.11-1.17 
Abnormalities cervical 
area 
11 19 58% 22 28 79% 0.13 0.38 0.10-1.35 
Ataxia / weakness
$





13 15 87% 12 25 48% 0.01* 6.14 1.43-26.35 
Death  11 24 46% 6 23 26% 0.16 2.40 0.70-8.20 
 
 





   P value (two-sample Wilcoxon 
rank sum test) 
Herd size  
(number of horses;  
mean  SD, range, n) 
54.6  33.7 
range 2-100 
n = 22 
23.3  31.9 
range 1-150 
n = 24 
< 0.001   
 N n % N n % P value (Fisher’s exact test) 
Herd activity       1.000   
 Riding school  9 24 38% 11 29 38%    
 Training centre 0 24 0% 1 29 3%    
 Breeding facility 5 24 21% 7 29 24%    
 Pleasure riding / home 7 24 29% 11 29 38%    
   P value  OR CI 95% 
Vaccination status          
 EHV vaccinated 16 23 70% 10 30 33% 0.01* 4.57 1.42-14.71 
 EHV vaccination < 6 
months before disease 
10 21 48% 8 29 28% 0.15 2.39 0.73-7.78 
 Tetanus vaccinated 21 22 95% 22 30 73% 0.07* 7.64 0.88-66.43 
Factors related to viral spread        
 Other sick horses since 3 
months  
13 20 65% 10 27 37% 0.13 2.46 0.77-7.79 
 New horse introduced in 
herd 
14 20 70% 5 26 19% 0.001* 9.80 2.50-48.41 
 Horse moved during last 
month 
6 21 29% 7 27 26% 0.84 1.14 0.32-4.11 
Motif to call veterinarian (multiple answers possible)     
 Hyperthermia 4 20 20% 2 28 7% 0.20 3.25 0.53-19.82 
 Ataxia, paresis 10 20 50% 8 28 29% 0.77 2.50 0.75-8.30 
 Recumbence 5 20 25% 2 28 7% NU NU NU 
 Lameness 0 20 0% 3 28 11% NU NU NU 
 Other / non-specific 
neurological signs 
3 20 15% 11 28 39% NU NU NU 
 Other motif 2 20 10% 7 28 25% NU NU NU 
Table 2. Clinical variables of horses with equine herpesvirus-
1 associated myeloencephalopathy and control horses 
Table 1. Signalment of horses with equine herpesvirus-1 
associated myeloencephalopathy and control horses 




P value (two sample Wilcoxon rank-
sum test) 
Age (years; 
mean  SD, range, 
n) 
12  4.5 
range 3-20 
n = 25 
10.7  6.5 
range 0.3-26 
n = 29 
0.24 
 N n % N n % P value (Fisher’s exact test) 
Breed       0.03* 
 Saddle horse 23 25 92% 18 28 64%  
 Pony  2 25 8% 9 28 32%  
 Draft horse 0 25 0% 0 28 0%  
 Donkey  0 25 0% 1 28 4%  
Sex       0.72 
 Mare 14 22 64% 15 31 48%  
 Stallion 5 25 20% 5 31 16%  
 Gelding 6 25 24% 11 31 35%  
 
